舒立松联合噻托溴铵治疗慢性阻塞性肺疾病的临床观察.docVIP

精品论文 参考文献 舒立松联合噻托溴铵治疗慢性阻塞性肺疾病的临床观察 杜宝奎 （内蒙古海拉尔区人民医院 021000） 　　【摘要】目的:探讨舒立松联合噻托溴铵治疗慢性阻塞性肺疾病的疗效。方法:选取我院诊断为慢性阻塞性肺疾病的患者87例，随机分为两组，观察组(给予舒立松联合噻托溴铵治疗)42例和对照组(给予噻托溴铵治疗)45例。所有患者均规律治疗12周，12周后比较两组的治疗效果。结果:规律治疗12周后，观察组患者的治疗有效率为95.24%，对照组为77.78%，观察组有效率明显高于对照组，比较差异有统计学意义(Plt;0.05)。两组患者均无明显不良反应发生。结论:舒立松联合噻托溴铵治疗慢性阻塞性肺疾病临床疗效明显，优于单纯噻托溴铵治疗，值得临床推广和应用。 　　【关键词】慢性阻塞性肺疾病 舒立松 噻托溴铵 临床观察 　　【中图分类号】R969.4 【文献标识码】A 【文章编号】1672-5085（2014）26-0051-02 　　Clinical observation of chronic obstructive pulmonary disease Shuli Song joint tiotropium therapy 　　【Abstract】Objective: To investigate Shuli Song combined therapy with tiotropium in chronic obstructive pulmonary disease. Methods: The hospital diagnosed patients with chronic obstructive pulmonary disease, 87 cases were randomly divided into two groups, the observation group (given Shuli Song joint tiotropium therapy) 42 cases and the control group (given tiotropium therapy) 45 cases. All patients were treated for 12 weeks law, comparing the two groups after 12 weeks of treatment. Results: After 12 weeks of treatment law, effective treatment of patients in the observation group was 95.24%, the control group was 77.78% in the observation group was significantly higher efficiency, the difference was statistically significant (P lt;0.05). Two patients had no significant adverse reactions occur. Conclusion: Shuli Song tiotropium combined clinical efficacy of treatment of chronic obstructive pulmonary disease was significantly better than treatment with tiotropium alone is worthy of promotion and application. 　　【Key words】chronic obstructive pulmonary disease; Shuli Song; tiotropium; clinical observation 　慢性阻塞性肺疾病(COPD)是以气流受限为特征的肺部疾病。具有病死率高、病情容易反复等特点，是呼吸内科的常见病、多发病之一。COPD在我国的发病率大约为0.6%-4.5%之间[1]，严重者会影响患者的生活质量。慢性气道堵塞和慢性气道炎症是COPD的主要特点，针对这一特点，治疗上，则主要是恢复气道通畅性和消除气道炎症为主，2004年5月，美国胸科学会和欧洲呼吸学会正式颁布了新的“COPD诊断和治疗指南”，新指南首次提出[2]吸人长效beta;受体激动剂与糖皮质激素的混合制剂能更有效的改善患者的肺功能，减轻症状，而且治疗过程更为简便。本文就87例COPD患者的治疗进行分析比较，旨